Vytrus Biotech S.A. - Asset Resilience Ratio

Latest as of December 2024: 0.01%

Vytrus Biotech S.A. (VYT) has an Asset Resilience Ratio of 0.01% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Vytrus Biotech S.A. balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€600.00
≈ $701.46 USD Cash + Short-term Investments

Total Assets

€11.13 Million
≈ $13.01 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2024)

This chart shows how Vytrus Biotech S.A.'s Asset Resilience Ratio has changed over time. See what is Vytrus Biotech S.A.'s book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Vytrus Biotech S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VYT company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €600.00 0.01%
Total Liquid Assets €600.00 0.01%

Asset Resilience Insights

  • Limited Liquidity: Vytrus Biotech S.A. maintains only 0.01% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Vytrus Biotech S.A. Industry Peers by Asset Resilience Ratio

Compare Vytrus Biotech S.A.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Royalty Pharma Plc
NASDAQ:RPRX
Biotechnology 0.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 30.29%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 4.52%
Shanghai Junshi Biosciences Co Ltd
SHG:688180
Biotechnology 4.28%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 83.49%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 41.74%

Annual Asset Resilience Ratio for Vytrus Biotech S.A. (2020–2024)

The table below shows the annual Asset Resilience Ratio data for Vytrus Biotech S.A..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.01% €600.00
≈ $701.46
€11.13 Million
≈ $13.01 Million
0.00pp
2023-12-31 0.01% €600.00
≈ $701.46
€9.31 Million
≈ $10.89 Million
0.00pp
2021-12-31 0.01% €520.00
≈ $607.93
€7.18 Million
≈ $8.40 Million
0.00pp
2020-12-31 0.01% €740.00
≈ $865.14
€6.21 Million
≈ $7.26 Million
--
pp = percentage points

About Vytrus Biotech S.A.

MC:VYT Spain Biotechnology
Market Cap
$159.95 Million
€136.82 Million EUR
Market Cap Rank
#19662 Global
#133 in Spain
Share Price
€19.60
Change (1 day)
+0.51%
52-Week Range
€3.04 - €19.80
All Time High
€19.80
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Ca… Read more